Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...
Tirzepatide outpacing Wegovy in the obesity space
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.
Why the Obesity Drug Revolution Is a Work in Progress
Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.
Screening for physical inactivity can cut risk of chronic illness, study suggests
Encouraging primary care physicians to screen patients for physical inactivity with a simple questionnaire can help identify ...
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025
INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...
Zacks.com on MSN5h
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Shares of Viking Therapeutics VKTX have lost nearly 22% in the past six months, significantly underperforming the industry’s ...
Pharma sector grappling with new realities at home and overseas
Indian pharmaceutical sector faces new challenges in 2025, from UCPMP implementation to global dynamics and opportunities in ...